标题
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 5, Pages e1308618
出版商
Informa UK Limited
发表日期
2017-03-29
DOI
10.1080/2162402x.2017.1308618
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
- (2016) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SLAM family receptors in normal immunity and immune pathologies
- (2016) Ning Wu et al. CURRENT OPINION IN IMMUNOLOGY
- CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance
- (2015) Giovanni Carulli et al. ACTA HAEMATOLOGICA
- Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses
- (2015) Marta Cuenca et al. JOURNAL OF IMMUNOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
- (2015) Sara Yousef et al. Human Vaccines & Immunotherapeutics
- Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
- (2015) Guoxing Wang et al. PLoS One
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy
- (2013) Régis T. Costello et al. IMMUNOLOGY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Involvement of CD244 in Regulating CD4+ T Cell Immunity in Patients with Active Tuberculosis
- (2013) Bingfen Yang et al. PLoS One
- Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
- (2012) A. Chaidos et al. BLOOD
- A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
- (2012) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Adaptor SAP Controls NK Cell Activation by Regulating the Enzymes Vav-1 and SHIP-1 and by Enhancing Conjugates with Target Cells
- (2012) Zhongjun Dong et al. IMMUNITY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutting Edge: Ly9 (CD229), a SLAM Family Receptor, Negatively Regulates the Development of Thymic Innate Memory-like CD8+ T and Invariant NKT Cells
- (2012) J. Sintes et al. JOURNAL OF IMMUNOLOGY
- Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins
- (2012) M Schoenhals et al. LEUKEMIA
- SLAM Family Receptors and SAP Adaptors in Immunity
- (2011) Jennifer L. Cannons et al. Annual Review of Immunology
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- CD48 as a novel molecular target for antibody therapy in multiple myeloma
- (2011) Naoki Hosen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus
- (2010) J. R. Kim et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function
- (2010) Bijan Raziorrouh et al. HEPATOLOGY
- Optimal Germinal Center Responses Require a Multistage T Cell:B Cell Adhesion Process Involving Integrins, SLAM-Associated Protein, and CD84
- (2010) Jennifer L. Cannons et al. IMMUNITY
- Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry
- (2010) Laia Llinàs et al. IMMUNOLOGY LETTERS
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
- (2010) Jose De Salort et al. IMMUNOLOGY LETTERS
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
- (2009) Mario-Ernesto Cruz-Munoz et al. NATURE IMMUNOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells
- (2008) Jordi Sintes et al. EXPERIMENTAL HEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now